Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 150 No. 4950 (2020)

Characterisation of clinical manifestations and treatment strategies for invasive beta-haemolytic streptococcal infections in a Swiss tertiary hospital

DOI
https://doi.org/10.4414/smw.2020.20378
Cite this as:
Swiss Med Wkly. 2020;150:w20378
Published
05.12.2020

Abstract

AIMS OF THE STUDY

Invasive streptococcal infections affect more than half a million patients worldwide every year and have a high lethality. Little is known about the epidemiology and microbiological characteristics of streptococcal infections in Switzerland. This case series study aims to describe the demographics, known risk factors for streptococcal skin and soft tissue infections, clinical presentations, treatment and outcomes of patients admitted to the University Hospital Zurich between 2000 and 2014 with invasive streptococcal infections caused by Streptococcus pyogenes (group A Streptococcus), Streptococcus dysgalactiae ssp. equisimilis or the Streptococcus anginosus group, as well as the microbiological characteristics of the clinical isolates.

METHODS

Data collected retrospectively from patients hospitalised between 2000 and 2014 with invasive streptococcal infections were analysed. M protein gene (emm) typing of the bacterial clinical isolates was carried out according to the Centers for Disease Control and Prevention guidelines.

RESULTS

A total of 86 patients with invasive beta-haemolytic streptococcal infections were included in this study, of which 49% presented with necrotising fasciitis. The median age was 44 years and half were female. The most common risk factor was acute skin lesions. C-reactive protein levels were significantly higher in patients with necrotising fasciitis, as were acute renal failure and distributive shock. Beta-lactam antibiotics were given to most patients, and intravenous immunoglobulins were given to 18% of patients within the first 24 hours. All patients suffering from necrotising fasciitis underwent surgery. The overall case fatality rate was 8.1% at 30 days post admission. All Group A Streptococcus strains were susceptible to penicillin and clindamycin, and we found resistance to tetracycline in 11.9% of strains. The most common emm-type isolated was emm1 (44.4%).

CONCLUSIONS

Invasive beta-haemolytic streptococcal infections, the most severe presentation of which is necrotising fasciitis, remain a serious clinical issue and require rapid diagnosis and treatment. This is the first representative analysis monitoring clinical and microbiological characteristics of patients with a severe invasive beta-haemolytic streptococcal infection and treated in Zurich, Switzerland. In addition to the detailed reporting of various clinical and microbiological characteristics, we show that C-reactive protein levels, acute renal failure and distributive shock were higher in the patients with necrotising fasciitis. We also found a low case fatality rate compared to other reports. The detailed clinical data and microbiological characteristics depicted in this study will lead to a better understanding of regional differences in severe invasive streptococcal infections.

References

  1. Bisno AL. Group A streptococcal infections and acute rheumatic fever. N Engl J Med. 1991;325(11):783–93. doi:.https://doi.org/10.1056/NEJM199109123251106
  2. Cone LA, Woodard DR, Schlievert PM, Tomory GS. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med. 1987;317(3):146–9. doi:.https://doi.org/10.1056/NEJM198707163170305
  3. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470–511. doi:.https://doi.org/10.1128/CMR.13.3.470
  4. Waddington CS, Snelling TL, Carapetis JR. Management of invasive group A streptococcal infections. J Infect. 2014;69(Suppl 1):S63–9. doi:.https://doi.org/10.1016/j.jinf.2014.08.005
  5. Parks T, Barrett L, Jones N. Invasive streptococcal disease: a review for clinicians. Br Med Bull. 2015;115(1):77–89. doi:.https://doi.org/10.1093/bmb/ldv027
  6. World Health Organization. The current evidence for the burden of group A streptococcal diseases. Geneva: World Health Organization; 2005.
  7. Lamagni TL, Darenberg J, Luca-Harari B, Siljander T, Efstratiou A, Henriques-Normark B, et al.; Strep-EURO Study Group. Epidemiology of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol. 2008;46(7):2359–67. doi:.https://doi.org/10.1128/JCM.00422-08
  8. Konrad D, Zbinden R, Kuster H, Hunziker UA ; Daniel Konrad, Reinhard Zbinden, Ha. Group G streptococcus sacroilitis with sepsis in a 15-y-old adolescent. Scand J Infect Dis. 1999;31(1):100–2. doi:.https://doi.org/10.1080/00365549950161998
  9. Bruun T, Kittang BR, de Hoog BJ, Aardal S, Flaatten HK, Langeland N, et al. Necrotizing soft tissue infections caused by Streptococcus pyogenes and Streptococcus dysgalactiae subsp. equisimilis of groups C and G in western Norway. Clin Microbiol Infect. 2013;19(12):E545–50. doi:.https://doi.org/10.1111/1469-0691.12276
  10. Vartian C, Lerner PI, Shlaes DM, Gopalakrishna KV. Infections due to Lancefield group G streptococci. Medicine (Baltimore). 1985;64(2):75–88. doi:.https://doi.org/10.1097/00005792-198503000-00001
  11. Broyles LN, Van Beneden C, Beall B, Facklam R, Shewmaker PL, Malpiedi P, et al. Population-based study of invasive disease due to beta-hemolytic streptococci of groups other than A and B. Clin Infect Dis. 2009;48(6):706–12. doi:.https://doi.org/10.1086/597035
  12. Sylvetsky N, Raveh D, Schlesinger Y, Rudensky B, Yinnon AM. Bacteremia due to beta-hemolytic Streptococcus group G: increasing incidence and clinical characteristics of patients. Am J Med. 2002;112(8):622–6. doi:.https://doi.org/10.1016/S0002-9343(02)01117-8
  13. Laupland KB, Ross T, Church DL, Gregson DB. Population-based surveillance of invasive pyogenic streptococcal infection in a large Canadian region. Clin Microbiol Infect. 2006;12(3):224–30. doi:.https://doi.org/10.1111/j.1469-0691.2005.01345.x
  14. Kittang BR, Bruun T, Langeland N, Mylvaganam H, Glambek M, Skrede S. Invasive group A, C and G streptococcal disease in western Norway: virulence gene profiles, clinical features and outcomes. Clin Microbiol Infect. 2011;17(3):358–64. doi:.https://doi.org/10.1111/j.1469-0691.2010.03253.x
  15. Descamps V, Aitken J, Lee MG. Hippocrates on necrotising fasciitis. Lancet. 1994;344(8921):556. doi:.https://doi.org/10.1016/S0140-6736(94)91956-9
  16. McCormick JK, Yarwood JM, Schlievert PM. Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol. 2001;55(1):77–104. doi:.https://doi.org/10.1146/annurev.micro.55.1.77
  17. Khamnuan P, Chongruksut W, Jearwattanakanok K, Patumanond J, Yodluangfun S, Tantraworasin A. Necrotizing fasciitis: risk factors of mortality. Risk Manag Healthc Policy. 2015;8:1–7.
  18. O’Loughlin RE, Roberson A, Cieslak PR, Lynfield R, Gershman K, Craig A, et al.; Active Bacterial Core Surveillance Team. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis. 2007;45(7):853–62. doi:.https://doi.org/10.1086/521264
  19. Nelson GE, Pondo T, Toews KA, Farley MM, Lindegren ML, Lynfield R, et al. Epidemiology of Invasive Group A Streptococcal Infections in the United States, 2005-2012. Clin Infect Dis. 2016;63(4):478–86. doi:.https://doi.org/10.1093/cid/ciw248
  20. Factor SH, Levine OS, Schwartz B, Harrison LH, Farley MM, McGeer A, et al. Invasive group A streptococcal disease: risk factors for adults. Emerg Infect Dis. 2003;9(8):970–7. doi:.https://doi.org/10.3201/eid0908.020745
  21. Luca-Harari B, Darenberg J, Neal S, Siljander T, Strakova L, Tanna A, et al.; Strep-EURO Study Group. Clinical and microbiological characteristics of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol. 2009;47(4):1155–65. doi:.https://doi.org/10.1128/JCM.02155-08
  22. Wahl RU, Lütticken R, Stanzel S, van der Linden M, Reinert RR. Epidemiology of invasive Streptococcus pyogenes infections in Germany, 1996-2002: results from a voluntary laboratory surveillance system. Clin Microbiol Infect. 2007;13(12):1173–8. doi:.https://doi.org/10.1111/j.1469-0691.2007.01821.x
  23. Olafsdottir LB, Erlendsdóttir H, Melo-Cristino J, Weinberger DM, Ramirez M, Kristinsson KG, et al. Invasive infections due to Streptococcus pyogenes: seasonal variation of severity and clinical characteristics, Iceland, 1975 to 2012. Euro Surveill. 2014;19(17):5–14. doi:.https://doi.org/10.2807/1560-7917.ES2014.19.17.20784
  24. Astorino T, Genrich I, Macgregor L, Victor CS, Eckhouse DR, Barbour L. Necrotizing fasciitis: early detection may save your patient’s limb. Orthop Nurs. 2009;28(2):70–6, quiz 77–8. doi:.https://doi.org/10.1097/NOR.0b013e318199ecb4
  25. Wong CH, Chang HC, Pasupathy S, Khin LW, Tan JL, Low CO. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am. 2003;85(8):1454–60. doi:.https://doi.org/10.2106/00004623-200308000-00005
  26. Bilton BD, Zibari GB, McMillan RW, Aultman DF, Dunn G, McDonald JC. Aggressive surgical management of necrotizing fasciitis serves to decrease mortality: a retrospective study. Am Surg. 1998;64(5):397–400, discussion 400–1.
  27. Carapetis JR, Jacoby P, Carville K, Ang SJ, Curtis N, Andrews R. Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections. Clin Infect Dis. 2014;59(3):358–65. doi:.https://doi.org/10.1093/cid/ciu304
  28. Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J. 1999;18(12):1096–100. doi:.https://doi.org/10.1097/00006454-199912000-00014
  29. Brown SD, Rybak MJ. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study. J Antimicrob Chemother. 2004;54(Suppl 1):i7–15. doi:.https://doi.org/10.1093/jac/dkh313
  30. Russell NE, Pachorek RE. Clindamycin in the treatment of streptococcal and staphylococcal toxic shock syndromes. Ann Pharmacother. 2000;34(7-8):936–9. doi:.https://doi.org/10.1345/aph.19095
  31. Imöhl M, Reinert RR, Mutscher C, van der Linden M. Macrolide susceptibility and serotype specific macrolide resistance of invasive isolates of Streptococcus pneumoniae in Germany from 1992 to 2008. BMC Microbiol. 2010;10(1):299. doi:.https://doi.org/10.1186/1471-2180-10-299
  32. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al.; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10–52. doi:.https://doi.org/10.1093/cid/ciu296
  33. Sriskandan S, Ferguson M, Elliot V, Faulkner L, Cohen J. Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation. J Antimicrob Chemother. 2006;58(1):117–24. doi:.https://doi.org/10.1093/jac/dkl173
  34. Tarnutzer A, Andreoni F, Keller N, Zürcher C, Norrby-Teglund A, Schüpbach RA, et al. Human polyspecific immunoglobulin attenuates group A streptococcal virulence factor activity and reduces disease severity in a murine necrotizing fasciitis model. Clin Microbiol Infect. 2019;25(4):512.e7–13. doi:.https://doi.org/10.1016/j.cmi.2018.07.007
  35. Kadri SS, Swihart BJ, Bonne SL, Hohmann SF, Hennessy LV, Louras P, et al. Impact of Intravenous Immunoglobulin on Survival in Necrotizing Fasciitis With Vasopressor-Dependent Shock: A Propensity Score-Matched Analysis From 130 US Hospitals. Clin Infect Dis. 2017;64(7):877–85.
  36. Sriskandan S, McKee A, Hall L, Cohen J. Comparative effects of clindamycin and ampicillin on superantigenic activity of Streptococcus pyogenes. J Antimicrob Chemother. 1997;40(2):275–7. doi:.https://doi.org/10.1093/jac/40.2.275
  37. Linnér A, Darenberg J, Sjölin J, Henriques-Normark B, Norrby-Teglund A. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis. 2014;59(6):851–7. doi:.https://doi.org/10.1093/cid/ciu449
  38. Fischetti VA. Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev. 1989;2(3):285–314. doi:.https://doi.org/10.1128/CMR.2.3.285
  39. Beall B, Facklam R, Thompson T. Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol. 1996;34(4):953–8. doi:.https://doi.org/10.1128/JCM.34.4.953-958.1996
  40. Darenberg J, Luca-Harari B, Jasir A, Sandgren A, Pettersson H, Schalén C, et al. Molecular and clinical characteristics of invasive group A streptococcal infection in Sweden. Clin Infect Dis. 2007;45(4):450–8. doi:.https://doi.org/10.1086/519936
  41. Chelsom J, Halstensen A, Chelsom J, Haga T, Høiby EA. Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet. 1994;344(8930):1111–5. doi:.https://doi.org/10.1016/S0140-6736(94)90629-7
  42. Commons RJ, Smeesters PR, Proft T, Fraser JD, Robins-Browne R, Curtis N. Streptococcal superantigens: categorization and clinical associations. Trends Mol Med. 2014;20(1):48–62. doi:.https://doi.org/10.1016/j.molmed.2013.10.004
  43. Watson DW. Host-parasite factors in group A streptococcal infections. Pyrogenic and other effects of immunologic distinct exotoxins related to scarlet fever toxins. J Exp Med. 1960;111:255–84. doi:.https://doi.org/10.1084/jem.111.2.255
  44. Seth A, Stern LJ, Ottenhoff TH, Engel I, Owen MJ, Lamb JR, et al. Binary and ternary complexes between T-cell receptor, class II MHC and superantigen in vitro. Nature. 1994;369(6478):324–7. doi:.https://doi.org/10.1038/369324a0
  45. Dellabona P, Peccoud J, Kappler J, Marrack P, Benoist C, Mathis D. Superantigens interact with MHC class II molecules outside of the antigen groove. Cell. 1990;62(6):1115–21. doi:.https://doi.org/10.1016/0092-8674(90)90388-U
  46. Reda KB, Kapur V, Mollick JA, Lamphear JG, Musser JM, Rich RR. Molecular characterization and phylogenetic distribution of the streptococcal superantigen gene (ssa) from Streptococcus pyogenes. Infect Immun. 1994;62(5):1867–74. doi:.https://doi.org/10.1128/IAI.62.5.1867-1874.1994
  47. Kuehl R, Tschudin-Sutter S, Siegemund M, Marsch S, Battegay M, Wetterauer C, et al. High Mortality of Non-Fournier Necrotizing Fasciitis With Enterobacteriales: Time to Rethink Classification? Clin Infect Dis. 2019;69(1):147–50. doi:.https://doi.org/10.1093/cid/ciy1011
  48. Rieger UM, Gugger CY, Farhadi J, Heider I, Andresen R, Pierer G, et al. Prognostic factors in necrotizing fasciitis and myositis: analysis of 16 consecutive cases at a single institution in Switzerland. Ann Plast Surg. 2007;58(5):523–30. doi:.https://doi.org/10.1097/01.sap.0000244978.27053.08
  49. Ruppen C, Rasmussen M, Casanova C, Sendi P. A 10-year observational study of Streptococcus dysgalactiae bacteraemia in adults: frequent occurrence among female intravenous drug users. Swiss Med Wkly. 2017;147:w14469.
  50. Schulthess B, Brodner K, Bloemberg GV, Zbinden R, Böttger EC, Hombach M. Identification of Gram-positive cocci by use of matrix-assisted laser desorption ionization-time of flight mass spectrometry: comparison of different preparation methods and implementation of a practical algorithm for routine diagnostics. J Clin Microbiol. 2013;51(6):1834–40. doi:.https://doi.org/10.1128/JCM.02654-12
  51. Clarridge JE, 3rd. Impact of 16S rRNA gene sequence analysis for identification of bacteria on clinical microbiology and infectious diseases. Clin Microbiol Rev. 2004;17(4):840–62. doi:.https://doi.org/10.1128/CMR.17.4.840-862.2004
  52. Matsuo M, Hiramatsu M, Singh M, Sasaki T, Hishinuma T, Yamamoto N, et al. Genetic and Transcriptomic Analyses of Ciprofloxacin-Tolerant Staphylococcus aureus Isolated by the Replica Plating Tolerance Isolation System (REPTIS). Antimicrob Agents Chemother. 2019;63(2):e02019-18. doi:.https://doi.org/10.1128/AAC.02019-18
  53. Moody MD, Padula J, Lizana D, Hall CT. Epidemiologic Characterization of Group a Streptococci by T-Agglutination and M-Precipitation Tests in the Public Health Laboratory. Health Lab Sci. 1965;2:149–62.
  54. Lintges M, Arlt S, Uciechowski P, Plümäkers B, Reinert RR, Al-Lahham A, et al. A new closed-tube multiplex real-time PCR to detect eleven superantigens of Streptococcus pyogenes identifies a strain without superantigen activity. Int J Med Microbiol. 2007;297(6):471–8. doi:.https://doi.org/10.1016/j.ijmm.2007.03.015
  55. Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966;45(4):493–6. doi:.https://doi.org/10.1093/ajcp/45.4_ts.493
  56. CLSI. Performance Standards for Antimicrobial Susceptibility testing. 29th edition. Wayne, PA: Clinical and Laboratory Standards Institute. 2019.
  57. Bevölkerung in Zahlen. 2020. Available from: https://www.zh.ch/de/soziales/bevoelkerungszahlen.html?keyword=bevoelkerung#/details/127@statistisches-amt-kanton-zuerich [cited 2020 September 9].
  58. Kaul R, McGeer A, Low DE, Green K, Schwartz B, Simor AE. Population-based surveillance for group A streptococcal necrotizing fasciitis: Clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study. Am J Med. 1997;103(1):18–24. doi:.https://doi.org/10.1016/S0002-9343(97)00160-5
  59. Lepoutre A, Doloy A, Bidet P, Leblond A, Perrocheau A, Bingen E, et al.; Microbiologists of the Epibac Network. Epidemiology of invasive Streptococcus pyogenes infections in France in 2007. J Clin Microbiol. 2011;49(12):4094–100. doi:.https://doi.org/10.1128/JCM.00070-11
  60. Luca-Harari B, Ekelund K, van der Linden M, Staum-Kaltoft M, Hammerum AM, Jasir A. Clinical and epidemiological aspects of invasive Streptococcus pyogenes infections in Denmark during 2003 and 2004. J Clin Microbiol. 2008;46(1):79–86. doi:.https://doi.org/10.1128/JCM.01626-07
  61. Imöhl M, Reinert RR, Ocklenburg C, van der Linden M. Epidemiology of invasive Streptococcus pyogenes disease in Germany during 2003-2007. FEMS Immunol Med Microbiol. 2010;58(3):389–96. doi:.https://doi.org/10.1111/j.1574-695X.2010.00652.x
  62. Wong CH, Khin LW, Heng KS, Tan KC, Low CO. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med. 2004;32(7):1535–41. doi:.https://doi.org/10.1097/01.CCM.0000129486.35458.7D
  63. Mehta S, McGeer A, Low DE, Hallett D, Bowman DJ, Grossman SL, et al. Morbidity and mortality of patients with invasive group A streptococcal infections admitted to the ICU. Chest. 2006;130(6):1679–86. doi:.https://doi.org/10.1016/S0012-3692(15)50887-8
  64. Ferguson ND, Fan E, Camporota L, Antonelli M, Anzueto A, Beale R, et al. The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med. 2012;38(10):1573–82. doi:.https://doi.org/10.1007/s00134-012-2682-1
  65. Parks T, Wilson C, Curtis N, Norrby-Teglund A, Sriskandan S. Polyspecific Intravenous Immunoglobulin in Clindamycin-treated Patients With Streptococcal Toxic Shock Syndrome: A Systematic Review and Meta-analysis. Clin Infect Dis. 2018;67(9):1434–6. doi:.https://doi.org/10.1093/cid/ciy401
  66. Madsen MB, Hjortrup PB, Hansen MB, Lange T, Norrby-Teglund A, Hyldegaard O, et al. Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): a randomised, blinded, placebo-controlled trial. Intensive Care Med. 2017;43(11):1585–93. doi:.https://doi.org/10.1007/s00134-017-4786-0
  67. Andreoni F, Ugolini F, Keller N, Neff A, Nizet V, Hollands A, et al. Immunoglobulin Attenuates Streptokinase-Mediated Virulence in Streptococcus dysgalactiae Subspecies equisimilis Necrotizing Fasciitis. J Infect Dis. 2018;217(2):270–9. doi:.https://doi.org/10.1093/infdis/jix560
  68. Elliott D, Kufera JA, Myers RA. The microbiology of necrotizing soft tissue infections. Am J Surg. 2000;179(5):361–6. doi:.https://doi.org/10.1016/S0002-9610(00)00360-3
  69. Siljander T, Lyytikäinen O, Vähäkuopus S, Snellman M, Jalava J, Vuopio J. Epidemiology, outcome and emm types of invasive group A streptococcal infections in Finland. Eur J Clin Microbiol Infect Dis. 2010;29(10):1229–35. doi:.https://doi.org/10.1007/s10096-010-0989-9
  70. Strus M, Heczko PB, Golińska E, Tomusiak A, Chmielarczyk A, Dorycka M, et al. The virulence factors of group A streptococcus strains isolated from invasive and non-invasive infections in Polish and German centres, 2009-2011. Eur J Clin Microbiol Infect Dis. 2017;36(9):1643–9. doi:.https://doi.org/10.1007/s10096-017-2978-8
  71. Cornaglia G, Ligozzi M, Mazzariol A, Valentini M, Orefici G, Fontana R ; The Italian Surveillance Group for Antimicrobial Resistance. Rapid increase of resistance to erythromycin and clindamycin in Streptococcus pyogenes in Italy, 1993-1995. Emerg Infect Dis. 1996;2(4):339–42. doi:.https://doi.org/10.3201/eid0204.960410
  72. Herruzo R, Chamorro L, García ME, González MC, López AM, Manceñido N, et al. Prevalence and antimicrobial-resistance of S. pneumoniae and S. pyogenes in healthy children in the region of Madrid. Int J Pediatr Otorhinolaryngol. 2002;65(2):117–23. doi:.https://doi.org/10.1016/S0165-5876(02)00145-3
  73. Sawai J, Hasegawa T, Kamimura T, Okamoto A, Ohmori D, Nosaka N, et al. Growth phase-dependent effect of clindamycin on production of exoproteins by Streptococcus pyogenes. Antimicrob Agents Chemother. 2007;51(2):461–7. doi:.https://doi.org/10.1128/AAC.00539-06
  74. Andreoni F, Zürcher C, Tarnutzer A, Schilcher K, Neff A, Keller N, et al. Clindamycin Affects Group A Streptococcus Virulence Factors and Improves Clinical Outcome. J Infect Dis. 2017;215(2):269–77.
  75. Imöhl M, van der Linden M. Antimicrobial Susceptibility of Invasive Streptococcus pyogenes Isolates in Germany during 2003-2013. PLoS One. 2015;10(9):e0137313. doi:.https://doi.org/10.1371/journal.pone.0137313

Most read articles by the same author(s)